<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0186-4866</journal-id>
<journal-title><![CDATA[Medicina interna de México]]></journal-title>
<abbrev-journal-title><![CDATA[Med. interna Méx.]]></abbrev-journal-title>
<issn>0186-4866</issn>
<publisher>
<publisher-name><![CDATA[Edición y Farmacia S.A. de C.V.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0186-48662018000600006</article-id>
<article-id pub-id-type="doi">10.24245/mim.v34i6.2617</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Control y evaluación de la microalbuminuria en una población del estado de Nayarit, México. Estudio realizado mediante la automedición a préstamo de la presión arterial]]></article-title>
<article-title xml:lang="en"><![CDATA[Control and evaluation of microalbuminuria in a population of the state of Nayarit, Mexico. Study conducted by self-measurement on loan of blood pressure.]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Delgado-Mejía]]></surname>
<given-names><![CDATA[Manuel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Delgado-Astorga]]></surname>
<given-names><![CDATA[Claudia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ávalos-Ruvalcaba]]></surname>
<given-names><![CDATA[Tomás]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Paredes-Casillas]]></surname>
<given-names><![CDATA[Patricia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[González-González]]></surname>
<given-names><![CDATA[Edgar]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,ISSSTE Hospital General Dr. Aquiles Calles Ramírez ]]></institution>
<addr-line><![CDATA[Tepic Nayarit]]></addr-line>
<country>México</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad Autónoma de Nayarit  ]]></institution>
<addr-line><![CDATA[Tepic Nayarit]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Nuevo Hospital Civil de Guadalajara Departamento de Medicina Interna ]]></institution>
<addr-line><![CDATA[Guadalajara Jalisco]]></addr-line>
<country>México</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Nuevo Hospital Civil de Guadalajara Departamento de Epidemiología ]]></institution>
<addr-line><![CDATA[Guadalajara Jalisco]]></addr-line>
<country>México</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2018</year>
</pub-date>
<volume>34</volume>
<numero>6</numero>
<fpage>864</fpage>
<lpage>873</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0186-48662018000600006&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0186-48662018000600006&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0186-48662018000600006&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen:  ANTECEDENTES Existen antecedentes de que el control estricto de las cifras de presión arterial puede repercutir favorablemente evitando la aparición de microalbuminuria y, por tanto, previniendo la nefropatía, asimismo, disminuye significativamente los desenlaces fatales por enfermedad cardiovascular y cerebrovascular.  OBJETIVO Demostrar que el control estricto de las cifras tensionales puede disminuir la microalbuminuria.  MATERIAL Y METODO  Estudio observacional y descriptivo efectuado de enero a diciembre de 2017, en el que se evaluaron pacientes con diagnóstico establecido de diabetes mellitus tipo 2, hipertensión arterial sistémica o ambas; la selección fue aleatoria. A estos pacientes se les incorporó en un protocolo de automedición a préstamo de la presión arterial. No se incluyeron pacientes con insuficiencia renal crónica.  RESULTADOS Se incluyeron 200 pacientes en quienes se midió la correlación entre múltiples variables y la existencia de microalbuminuria. Se encontró correlación estadísticamente significativa al segmentar a los pacientes según la clasificación de ACC/AHA 2017 y posterior al ajuste de la dosis de antihipertensivo con valor de p = 0.00001.  CONCLUSIONES Con estos hallazgos podría plantearse el ajuste del tratamiento con base en las cifras tensionales del paciente, sin importar si el tratamiento es con IECAS o ARA II.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract:  BACKGROUND There are precedents that the strict control of the blood pressure figures can have a favorable impact avoiding the development of microalbuminuria, and therefore preventing the appearance of nephropathy, as well as significantly reducing fatal outcomes due to cardiovascular and cerebrovascular disease.  OBJECTIVE  To show that strict control of tension figures can impact decreasing the microalbuminuria.  MATERIAL AND METHOD  An observational and descriptive study was done from January to December 2017 with patients with an established diagnosis of type 2 diabetes mellitus and/or systemic hypertension, with random selection. These patients were incorporated into a Self-Commissioning Protocol to loan blood pressure. Patients with chronic kidney disease were not included.  RESULTS  There were included 200 patients. The correlation between multiple variables and the presence of microalbuminuria was measured finding a statistically significant correlation when segmenting patients according to the ACC/AHA 2017 classification and after adjusting the antihypertensive dose with p = 0.00001.  CONCLUSIONS  Treatment should be adjusted based on the patient&#8217;s blood pressure, regardless of whether the treatment is with IECAS or ARA II.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Presión arterial]]></kwd>
<kwd lng="es"><![CDATA[microalbuminuria]]></kwd>
<kwd lng="es"><![CDATA[antihipertensivo]]></kwd>
<kwd lng="en"><![CDATA[Blood pressure]]></kwd>
<kwd lng="en"><![CDATA[Microalbuminuria]]></kwd>
<kwd lng="en"><![CDATA[Antihypertensive]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="">
<collab>World Health Organization</collab>
<source><![CDATA[The Diabetes Program]]></source>
<year>2004</year>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ramuzzi]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Shieppati]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ruggenenti]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Nephropathy in patients with type 2 diabetes]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2002</year>
<volume>346</volume>
<page-range>1145-51</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ritz]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Albuminuria and vascular damage- the vicious twins]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2003</year>
<volume>348</volume>
<page-range>2349-52</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gall]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Jouggard]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Parving]]></surname>
<given-names><![CDATA[HH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus prospective, observational study]]></article-title>
<source><![CDATA[BMJ]]></source>
<year>1997</year>
<volume>324</volume>
<page-range>783-8</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Adler]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Stevens]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Manley]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[Holman]]></surname>
<given-names><![CDATA[RR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Development and progression of nephropathy in type 2 diabetes the United Kingdom Prospective Diabetes Study (UKPDS 64)]]></article-title>
<source><![CDATA[Kidney Int]]></source>
<year>2003</year>
<volume>63</volume>
<page-range>225-32</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Perkins]]></surname>
<given-names><![CDATA[BA]]></given-names>
</name>
<name>
<surname><![CDATA[Ficociello]]></surname>
<given-names><![CDATA[LH]]></given-names>
</name>
<name>
<surname><![CDATA[Silva]]></surname>
<given-names><![CDATA[KH]]></given-names>
</name>
<name>
<surname><![CDATA[Finkelstein]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Warran]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Regression of microalbuminuria in type 1 diabetes]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2003</year>
<volume>348</volume>
<page-range>2285-93</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Parving]]></surname>
<given-names><![CDATA[HH]]></given-names>
</name>
<name>
<surname><![CDATA[Lehenert]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Brochner-Mortensen]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Gomis]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Andersen]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Arner]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2001</year>
<volume>345</volume>
<page-range>870-8</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mogensen]]></surname>
<given-names><![CDATA[CE.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Microalbuminuria predicts clinical proteinuria early mortality in maturity-onset diabetes]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>1984</year>
<volume>310</volume>
<page-range>356-60</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nelson]]></surname>
<given-names><![CDATA[RG]]></given-names>
</name>
<name>
<surname><![CDATA[Knowler]]></surname>
<given-names><![CDATA[WC]]></given-names>
</name>
<name>
<surname><![CDATA[Pettit]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Bennet]]></surname>
<given-names><![CDATA[PH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Assessing risk of overt nephropaty in diabetic patients from albumin excretion in untimed urine specimens]]></article-title>
<source><![CDATA[Arch Intern Med]]></source>
<year>1991</year>
<volume>151</volume>
<page-range>1761-0</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schrier]]></surname>
<given-names><![CDATA[RW]]></given-names>
</name>
<name>
<surname><![CDATA[Estacio]]></surname>
<given-names><![CDATA[RO]]></given-names>
</name>
<name>
<surname><![CDATA[Esler]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Mehler]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes]]></article-title>
<source><![CDATA[Kidney Int]]></source>
<year>2002</year>
<volume>61</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>1086-97</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Eurich]]></surname>
<given-names><![CDATA[DT]]></given-names>
</name>
<name>
<surname><![CDATA[Majumdar]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Tsuyuki]]></surname>
<given-names><![CDATA[RT]]></given-names>
</name>
<name>
<surname><![CDATA[Johanson]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Reduced mortality associated with the use of ACE Inhibitors in patients with type 2 diabetes]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2004</year>
<volume>27</volume>
<page-range>1330-4</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Parving]]></surname>
<given-names><![CDATA[HH]]></given-names>
</name>
<name>
<surname><![CDATA[Mauer]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ritz]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diabetic nephropathy]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Brenner]]></surname>
<given-names><![CDATA[BM]]></given-names>
</name>
</person-group>
<collab>ed</collab>
<source><![CDATA[Brenner &amp; Rectors.The Kidney,]]></source>
<year>2004</year>
<edition>7</edition>
<publisher-loc><![CDATA[Philadephia ]]></publisher-loc>
<publisher-name><![CDATA[Saunders]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Selvin]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Marinopoulus]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Berkenblit]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Meta-analysis Glycosyladehemoglobin and cardiovascular disease in diabetes mellitus]]></article-title>
<source><![CDATA[Ann Intern Med]]></source>
<year>2004</year>
<volume>141</volume>
<page-range>421-31</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dinneen]]></surname>
<given-names><![CDATA[SF]]></given-names>
</name>
<name>
<surname><![CDATA[Gerstein]]></surname>
<given-names><![CDATA[HC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus a systematic overview of the literature]]></article-title>
<source><![CDATA[Arch Intern Med]]></source>
<year>1997</year>
<volume>157</volume>
<page-range>1413-8</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brenner]]></surname>
<given-names><![CDATA[BM]]></given-names>
</name>
<name>
<surname><![CDATA[Cooper]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2001</year>
<volume>345</volume>
<page-range>861</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ravit]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Brosh]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Levi]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Bar Dayan]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuria patients with type 2 diabetes mellitus a randomized controlled trial]]></article-title>
<source><![CDATA[Ann Intern Med]]></source>
<year>1998</year>
<volume>128</volume>
<page-range>982-8</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Calvo-Vargas]]></surname>
<given-names><![CDATA[CG]]></given-names>
</name>
<name>
<surname><![CDATA[Padilla]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Medina]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Reproducibility end cost of home blood pressure using the "Loaned self-measurement model" Blood Pressure]]></article-title>
<source><![CDATA[Monit]]></source>
<year>2001</year>
<volume>6</volume>
<page-range>1-8</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Calvo-Vargas]]></surname>
<given-names><![CDATA[CG]]></given-names>
</name>
<name>
<surname><![CDATA[Rubio Guerra]]></surname>
<given-names><![CDATA[AF]]></given-names>
</name>
<name>
<surname><![CDATA[Galarza-Delgado]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Garcia]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Delgado-Mejía]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Eficacia del valsartan y la hidroclorotiazida en el tratamiento de la hipertensión arterial esencial Estudio realizado mediante la automedicion a préstamo de la presión arterial]]></article-title>
<source><![CDATA[Med Int Mex]]></source>
<year>2002</year>
<volume>18</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>67-74</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Emdin]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Rahimi]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Neal]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Callender]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Perkovic]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Blood pressure lowering in type 2 diabetes a systematic review and meta-analysis]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2015</year>
<volume>313</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>603-15</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ruggementi]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Remuzzi]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The diagnosis of renal involvement in non-insulin-dependent diabetes mellitus]]></article-title>
<source><![CDATA[Curr-Opin Nephrol Hypertens]]></source>
<year>1997</year>
<volume>6</volume>
<page-range>141-51</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<collab>UK Prospective Diabetes Study Group</collab>
<article-title xml:lang=""><![CDATA[Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>1998</year>
<volume>352</volume>
<page-range>837-53</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<collab>BENEDICT Group</collab>
<article-title xml:lang=""><![CDATA[The Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Design and baseline characteristics]]></article-title>
<source><![CDATA[Control Clin Trials]]></source>
<year>2003</year>
<volume>24</volume>
<page-range>442-61</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[High blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes]]></article-title>
<source><![CDATA[UKPDS 38. BMJ]]></source>
<year>1998</year>
<volume>317</volume>
<page-range>703-13</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lindholm]]></surname>
<given-names><![CDATA[LH]]></given-names>
</name>
<name>
<surname><![CDATA[Ibsen]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Dahlof]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiovascular morbidity and mortality in patients with diabetes in the losartan intervention For Endpoint reduction in hypertension Study (LIFE) a randomized trial against atenolol]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2002</year>
<volume>359</volume>
<page-range>1004-10</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lewis]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Hunsicker]]></surname>
<given-names><![CDATA[LG]]></given-names>
</name>
<name>
<surname><![CDATA[Clarke]]></surname>
<given-names><![CDATA[WR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Renoprotective effect of the angiotensin receptor antagonist irbersartan in patients with nephropathy due to type 2 diabetes]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2001</year>
<volume>345</volume>
<page-range>851-60</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<collab>Heart outcomes Prevention Evaluation (HOPE)</collab>
<article-title xml:lang=""><![CDATA[Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the (HOPE) study, and MICRO-HOPE substudy]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2000</year>
<volume>355</volume>
<page-range>253-9</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Viberty]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Mogensen]]></surname>
<given-names><![CDATA[CE]]></given-names>
</name>
<name>
<surname><![CDATA[Groop]]></surname>
<given-names><![CDATA[LC]]></given-names>
</name>
<name>
<surname><![CDATA[Pauls]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbumiuria]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>1994</year>
<volume>271</volume>
<page-range>275-9</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kaplan]]></surname>
<given-names><![CDATA[NM]]></given-names>
</name>
</person-group>
<source><![CDATA[Clinical Hypertension]]></source>
<year>1998</year>
<edition>7</edition>
<publisher-loc><![CDATA[Baltimore ]]></publisher-loc>
<publisher-name><![CDATA[Williams &amp; Wilkins]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Calvo]]></surname>
<given-names><![CDATA[GC]]></given-names>
</name>
</person-group>
<source><![CDATA[La atención del paciente con hipertensión arterial.Un enfoque para el consultorio]]></source>
<year>1999</year>
<publisher-loc><![CDATA[Mexico ]]></publisher-loc>
<publisher-name><![CDATA[JGH editores]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Calvo-Vargas]]></surname>
<given-names><![CDATA[CG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Nuevos retos del control de la hipertensión arterial en México]]></article-title>
<source><![CDATA[Rev Med IMSS (Mex)]]></source>
<year>1998</year>
<volume>36</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>199-205</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Thijs]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Staessen]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Celis]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[de Gaudemaris]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Imail]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Julius]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Reference values for self-recorded blood pressure meta-analysis of summary date]]></article-title>
<source><![CDATA[Arch Intern Med]]></source>
<year>1998</year>
<volume>158</volume>
<page-range>481-8</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stanton]]></surname>
<given-names><![CDATA[RC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical challenges in diagnosis and management of diabetic kidney disease]]></article-title>
<source><![CDATA[Am J Kidney Dis]]></source>
<year>2014</year>
<volume>63</volume>
<numero>Suppl 2</numero>
<issue>Suppl 2</issue>
<page-range>S3-S21</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Caramori]]></surname>
<given-names><![CDATA[MI]]></given-names>
</name>
<name>
<surname><![CDATA[Fioretto]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Maurer]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Low glomerular filtration rate in normoalbuminuric type I diabetic patients an indicator of more advanced glomerular lesions]]></article-title>
<source><![CDATA[Diabetes]]></source>
<year>2003</year>
<volume>52</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>1056-640</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dwyer]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Parving]]></surname>
<given-names><![CDATA[HH]]></given-names>
</name>
<name>
<surname><![CDATA[Ravid]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ramuzzi]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Lewis]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Renal dysfunction in the presence of normoalbuminuria in type 2 diabetes results from the DEMAND Study]]></article-title>
<source><![CDATA[Cardio Renal Med]]></source>
<year>2012</year>
<volume>2</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-10</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<collab>The Diabetes Control and Complications Trial Research Group</collab>
<article-title xml:lang=""><![CDATA[The effect of intensive treatment of diabetes on the development end progression of long-term complications in insulin dependent diabetes mellitus]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>1993</year>
<volume>329</volume>
<numero>14</numero>
<issue>14</issue>
<page-range>977-86</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chakkarwar]]></surname>
<given-names><![CDATA[VA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Smoking in diabetic nephropathy sparks in the fuel tank]]></article-title>
<source><![CDATA[Word J Diabetes]]></source>
<year>2012</year>
<volume>3</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>186-95</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<collab>Clinical Practice Guidelines</collab>
<article-title xml:lang=""><![CDATA[Diabetes]]></article-title>
<source><![CDATA[Care]]></source>
<year>2013</year>
<volume>36</volume>
<numero>Suppl 1</numero>
<issue>Suppl 1</issue>
<page-range>529-31</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cushman]]></surname>
<given-names><![CDATA[WC]]></given-names>
</name>
<name>
<surname><![CDATA[Evans]]></surname>
<given-names><![CDATA[GW]]></given-names>
</name>
<name>
<surname><![CDATA[Bryngton]]></surname>
<given-names><![CDATA[RP]]></given-names>
</name>
</person-group>
<collab>Accord Study Group</collab>
<article-title xml:lang=""><![CDATA[Effects of intensive blood-pressure control in type 2 diabetes mellitus]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2010</year>
<volume>362</volume>
<numero>17</numero>
<issue>17</issue>
<page-range>1575-85</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Parving]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[N Engl]]></article-title>
<collab>for the ALTITUDE Investigators</collab>
<source><![CDATA[J Med]]></source>
<year>2012</year>
<volume>367</volume>
<page-range>2204-13</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
